Natalizumab in pediatric multiple sclerosis: Results of a cohort of 55 cases

A. Ghezzi, C. Pozzilli, L. M E Grimaldi, L. Moiola, V. Brescia-Morra, A. Lugaresi, G. Lus, F. Rinaldi, M. A. Rocca, M. Trojano, A. Bianchi, G. Comi, M. Filippi

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. Objective: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients. Methods: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment. Results: The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p <0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients. Conclusions: NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.

Original languageEnglish
Pages (from-to)1106-1112
Number of pages7
JournalMultiple Sclerosis Journal
Volume19
Issue number8
DOIs
Publication statusPublished - 2013

Fingerprint

Multiple Sclerosis
Pediatrics
Recurrence
Natalizumab
Magnetic Resonance Imaging
Anti-Idiotypic Antibodies
Therapeutics

Keywords

  • adolescence
  • childhood
  • Multiple sclerosis
  • natalizumab

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Natalizumab in pediatric multiple sclerosis : Results of a cohort of 55 cases. / Ghezzi, A.; Pozzilli, C.; Grimaldi, L. M E; Moiola, L.; Brescia-Morra, V.; Lugaresi, A.; Lus, G.; Rinaldi, F.; Rocca, M. A.; Trojano, M.; Bianchi, A.; Comi, G.; Filippi, M.

In: Multiple Sclerosis Journal, Vol. 19, No. 8, 2013, p. 1106-1112.

Research output: Contribution to journalArticle

Ghezzi, A, Pozzilli, C, Grimaldi, LME, Moiola, L, Brescia-Morra, V, Lugaresi, A, Lus, G, Rinaldi, F, Rocca, MA, Trojano, M, Bianchi, A, Comi, G & Filippi, M 2013, 'Natalizumab in pediatric multiple sclerosis: Results of a cohort of 55 cases', Multiple Sclerosis Journal, vol. 19, no. 8, pp. 1106-1112. https://doi.org/10.1177/1352458512471878
Ghezzi, A. ; Pozzilli, C. ; Grimaldi, L. M E ; Moiola, L. ; Brescia-Morra, V. ; Lugaresi, A. ; Lus, G. ; Rinaldi, F. ; Rocca, M. A. ; Trojano, M. ; Bianchi, A. ; Comi, G. ; Filippi, M. / Natalizumab in pediatric multiple sclerosis : Results of a cohort of 55 cases. In: Multiple Sclerosis Journal. 2013 ; Vol. 19, No. 8. pp. 1106-1112.
@article{ad8525ecf79c4694b4497135d874aebd,
title = "Natalizumab in pediatric multiple sclerosis: Results of a cohort of 55 cases",
abstract = "Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. Objective: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients. Methods: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment. Results: The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p <0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients. Conclusions: NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.",
keywords = "adolescence, childhood, Multiple sclerosis, natalizumab",
author = "A. Ghezzi and C. Pozzilli and Grimaldi, {L. M E} and L. Moiola and V. Brescia-Morra and A. Lugaresi and G. Lus and F. Rinaldi and Rocca, {M. A.} and M. Trojano and A. Bianchi and G. Comi and M. Filippi",
year = "2013",
doi = "10.1177/1352458512471878",
language = "English",
volume = "19",
pages = "1106--1112",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Natalizumab in pediatric multiple sclerosis

T2 - Results of a cohort of 55 cases

AU - Ghezzi, A.

AU - Pozzilli, C.

AU - Grimaldi, L. M E

AU - Moiola, L.

AU - Brescia-Morra, V.

AU - Lugaresi, A.

AU - Lus, G.

AU - Rinaldi, F.

AU - Rocca, M. A.

AU - Trojano, M.

AU - Bianchi, A.

AU - Comi, G.

AU - Filippi, M.

PY - 2013

Y1 - 2013

N2 - Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. Objective: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients. Methods: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment. Results: The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p <0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients. Conclusions: NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.

AB - Background: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients. Objective: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients. Methods: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment. Results: The study included 55 patients (mean age: 14.4 years, mean number of relapses: 4.4, pre-treatment mean disease duration: 25.5 months). They received a median number of 26 infusions. Three relapses occurred during the follow-up, one female patient continued to deteriorate in cognitive functioning. Mean Expanded Disability Status Scale (EDSS) scores decreased from 2.7 to 1.9 at the last visit (p <0.001). During the follow-up the majority of patients remained free from MRI activity. Transient and mild clinical adverse events occurred in 20 patients. Mild hematological abnormalities occurred in seven patients. Anti-JCV antibodies were detected in 20/51 tested patients. Conclusions: NA was well tolerated in all patients. A strong suppression of disease activity was observed in the majority of patients during the follow-up.

KW - adolescence

KW - childhood

KW - Multiple sclerosis

KW - natalizumab

UR - http://www.scopus.com/inward/record.url?scp=84879429292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879429292&partnerID=8YFLogxK

U2 - 10.1177/1352458512471878

DO - 10.1177/1352458512471878

M3 - Article

C2 - 23401129

AN - SCOPUS:84879429292

VL - 19

SP - 1106

EP - 1112

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 8

ER -